Everlywell's $249 AI Test Reads Mammograms for Cancer Risk
Update, Oct. 3: two follow-ups since launch day. First, the guideline hedge in this article is now retired — the 2026 NCCN Clinical Practice Guidelines for Breast Cancer Screening and Diagnosis include AI-based mammogram risk assessment as an option for identifying increased risk from age 35 (confirmed by Techstrong.ai and the launch announcement's guideline citation). Second, new practical details from Inc.com's Oct. 2 interview: the $249 test is HSA/FSA-eligible, Everlywell pulls your mammogram imagery electronically so there's no CD-chasing, and eligibility excludes women with a known BRCA mutation or those currently in cancer treatment. Worth knowing for the intervention question: Lehman says risk scores "change meaningfully over time," and the team is studying whether intervention can bring scores down — with low-dose Tamoxifen lowering estrogen-receptor-positive risk by up to 50% in some women. Everlywell's $249 AI Test Reads Mammograms for Cancer Risk...